A view on drug resistance in cancer
Open accessAbstract
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Low dependency on K-Ras signaling could confer intrinsic resistance to K-RasG12C inhibitors.
“Mechanistically, low dependency on K-Ras signaling could confer intrinsic resistance to K-RasG12C inhibitors.12,58,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [61]
In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [61]
Complete and durable responses to targeted cancer therapies are rare in patients with advanced-stage cancers.
“Complete and durable responses to targeted cancer therapies are rare in patients with advanced-stage cancers.61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471 · see citing works
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · see citing works
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894 · see citing works
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · see citing works
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Self-citationOsimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276 · see citing works
Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129 · see citing works
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · see citing works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · see citing works
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · see citing works
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works
Self-citationLiquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · see citing works
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · see citing works
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,747 · see citing works
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,585 · see citing works
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · see citing works
Self-citationAlectinib versus Crizotinib in Untreated <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · see citing works
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452 · see citing works
Andrews, D. W., Scott, C., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner‐Wasik, M., Demas, W. F., Ryu, J. K., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,418 · see citing works
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · see citing works
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271 · see citing works
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · see citing works
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,941 · see citing works
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,901 · see citing works
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · see citing works
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · see citing works
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal‐Hanjani, M., Constantin, T. P., Salari, R., Quesne, J. P. C. L., Moore, D. A., Veeriah, S., Rosenthal, R., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,880 · see citing works
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806 · see citing works
(1977) · PubMed · Cited by 1,801 · see citing works
Vogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770 · see citing works
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575 · see citing works
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C. A., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R. B., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564 · see citing works
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,551 · see citing works
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M., & Shendure, J. (2016) · Cell · doi:10.1016/j.cell.2015.11.050 · Cited by 1,462 · see citing works
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362 · see citing works
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333 · see citing works
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., Lena, M. D., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329 · see citing works
Forshew, T., Murtaza, M., Parkinson, C., Gale, D. G., Tsui, D. W. Y., Kaper, F., Dawson, S., Piskorz, A., Jimenez‐Liñan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,298 · see citing works
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,252 · see citing works
Self-citationDetection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,205 · see citing works
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,155 · see citing works
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J. A., le Coutre, P., PAQUETTE, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,141 · see citing works
Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus
Lo, Y. M. D., Chan, K. C. A., Sun, H., Chen, E. Z., Jiang, P., Lun, F. M. F., Zheng, Y. W. L., Leung, T. Y., Lau, T. K., Cantor, C. R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001720 · Cited by 1,102 · see citing works
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,091 · see citing works
Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,063 · see citing works
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,051 · see citing works
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,031 · see citing works
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works
Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Chen, Q., Boire, A., Jin, X., Valiente, M., Er, E. E., Lopez-Soto, A., S. Jacob, L., Patwa, R., Shah, H., Xu, K., et al. (2016) · Nature · doi:10.1038/nature18268 · Cited by 969 · see citing works
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · see citing works
Self-citationCMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946 · see citing works
Oser, M. G., Niederst, M. J., Sequist, L. V. D., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 939 · see citing works
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Hryniuk, W. M., & Bush, H. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1281 · Cited by 894 · see citing works
Laird, A. K. (1964) · British Journal of Cancer · doi:10.1038/bjc.1964.55 · Cited by 880 · see citing works
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
Valiente, M., Obenauf, A. C., Jin, X., Chen, Q., Zhang, X. H.-F., Lee, D. J., Chaft, J. E., Kris, M. G., Huse, J. T., Brogi, E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.040 · Cited by 871 · see citing works
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870 · see citing works
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866 · see citing works
Self-citationOvercoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Henau, O. D., Rausch, M. P., Winkler, D. A., Campesato, L. F., Liu, C., Hirschhorn-Cymerman, D., Budhu, S., Ghosh, A., Pink, M. M., Tchaicha, J. H., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 862 · see citing works
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · see citing works
Dressman, D. C., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 845 · see citing works
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J. R., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 822 · see citing works
Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer
Chan, K. C. A., Woo, J. K. S., King, A. D., Zee, B. C.-Y., Lam, W. K., Chan, S. L., Chu, S. W. I., Mak, C., Tse, I. O. L., Leung, S. Y. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701717 · Cited by 792 · see citing works
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 755 · see citing works
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 743 · see citing works
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · see citing works
GOODMAN, L. S. (1946) · JAMA · doi:10.1001/jama.1946.02870380008004 · Cited by 700 · see citing works
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685 · see citing works
Fragment Length of Circulating Tumor DNA
Underhill, H. R., Kitzman, J. O., Hellwig, S., Welker, N. C., Daza, R. M., Baker, D. N., Gligorich, K. M., Rostomily, R., Bronner, M. P., & Shendure, J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006162 · Cited by 675 · see citing works
Synthetic lethality and cancer
O’Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 658 · see citing works
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658 · see citing works
Microsatellite alterations in serum DNA of head and neck cancer patients
Nawroz, H., Koch, W. M., Anker, P., Stroun, M., & Sidransky, D. (1996) · Nature Medicine · doi:10.1038/nm0996-1035 · Cited by 656 · see citing works
Microsatellite alterations in plasma DNA of small cell lung cancer patients
Chen, X. Q., Stroun, M., Magnenat, J.-L., Nicod, L. P., Kurt, A.-M., Lyautey, J., Lederrey, C., & Anker, P. (1996) · Nature Medicine · doi:10.1038/nm0996-1033 · Cited by 647 · see citing works
Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission
Thomas, E. D., Buckner, C. D., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Sale, G. E., Sanders, J. E., Singer, J. W., Shulman, H. M., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909133011109 · Cited by 641 · see citing works
Benefits and Harms of Breast Cancer Screening
Myers, E. R., Moorman, P. G., Gierisch, J. M., Havrilesky, L. J., Grimm, L. J., Ghate, S. V., Davidson, B. A., Mongtomery, R. C., Crowley, M. J., McCrory, D. C., et al. (2015) · JAMA · doi:10.1001/jama.2015.13183 · Cited by 639 · see citing works
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638 · see citing works
Sternberg, C. N., Mulder, P. H. M. D., Schornagel, J. H., Théodore, C., Fosså, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 629 · see citing works
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J. G., Jahnke, W., Cowan‐Jacob, S. W., Loo, A. T., Furet, P., Marzinzik, A. L., Pellé, X., Donovan, J., Zhu, W. S., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 622 · see citing works
Identification of tissue-specific cell death using methylation patterns of circulating DNA
Lehmann‐Werman, R., Neiman, D., Zemmour, H., Moss, J., Magenheim, J., Vaknin‐Dembinsky, A., Rubertsson, S., Nellgård, B., Blennow, K., Zetterberg, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519286113 · Cited by 618 · see citing works
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works
Schiavon, G., Hrebien, S., García-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., López‐Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 589 · see citing works
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588 · see citing works
Self-citationTumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585 · see citing works
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562 · see citing works
Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543 · see citing works
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 518 · see citing works
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507 · see citing works
Intratumor Heterogeneity: Seeing the Wood for the Trees
Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L., & Swanton, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003854 · Cited by 487 · see citing works
Cancer of the breast: Size of neoplasm and prognosis
Fisher, B., Slack, N. H., Bross, I. D., & Cooperating Investigators (1969) · Cancer · doi:10.1002/1097-0142(196911)24:5 · Cited by 486 · see citing works
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 479 · see citing works
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · see citing works
Murtaza, M., Dawson, S., McNamara, K. L., Rueda, O. M., Provenzano, E., Grant, J. W., Chin, S., Tsui, D. W. Y., Marass, F., Gale, D. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms9760 · Cited by 478 · see citing works
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476 · see citing works
Self-citationCurability of Advanced Hodgkin's Disease with Chemotherapy
DeVita, V. T., SIMON, R. M., HUBBARD, S. M., YOUNG, R. C., BERARD, C. W., MOXLEY, J. H., FREI, E., CARBONE, P. P., & CANELLOS, G. P. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-5-587 · Cited by 470 · see citing works
Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer
Mok, T. S. K., Wu, Y.-L. L. C., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S., Shepherd, F. A., He, Y.-M., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · QUT ePrints (Queensland University of Technology) · Cited by 463 · see citing works
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452 · see citing works
Drilon, A. E. D. C., Nagasubramanian, R., Blake, J. F., Ku, N. C., Tuch, B. B., Ebata, K. T., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 452 · see citing works
Self-citationEarly stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
Abbosh, C., Birkbak, N. J., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0058-3 · Cited by 451 · see citing works
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448 · see citing works
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · see citing works
Self-citationPlasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N. A., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 437 · see citing works
Sullivan, R. J., Infante, J. R., Jankú, F., Wong, D. J. L., Sosman, J. A., Keedy, V. L., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 436 · see citing works
Self-citationBosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432 · see citing works
Self-citationSynthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420 · see citing works
Limits to Personalized Cancer Medicine
Tannock, I. F., & Hickman, J. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1607705 · Cited by 418 · see citing works
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality
Martin, R. M., Donovan, J., Turner, E. L., Metcalfe, C. D., Young, G., Walsh, E. I., Lane, J. A., Noble, S., Oliver, S. E., Evans, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.0154 · Cited by 415 · see citing works
Evolutionary Determinants of Cancer
Greaves, M. F. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 411 · see citing works
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 408 · see citing works
Gray, R. G., Bradley, R., Braybrooke, J. P., Liu, Z., Peto, R., Davies, L. C., Dodwell, D. J., McGale, P., Pan, H., Taylor, C. W., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 402 · see citing works
Determinants and clinical implications of chromosomal instability in cancer
Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386 · see citing works
Isolation and characterization of DNA from the plasma of cancer patients
Stroun, M., Anker, P., Lyautey, J., Lederrey, C., & Maurice, P. A. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90266-5 · Cited by 373 · see citing works
Complement Component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis.
Boire, A., Zou, Y., Shieh, J., Macalinao, D. G., Pentsova, E., & Massagué, J. (2017) · Cell · doi:10.1016/j.cell.2017.02.025 · Cited by 366 · see citing works
Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K., Benezeder, T., Auer, M., Pischler, C., Mannweiler, S., et al. (2013) · Genome Medicine · doi:10.1186/gm434 · Cited by 356 · see citing works
KRAS Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Huang, L. (2009) · Journal of Evidence-Based Medicine · Cited by 338 · see citing works
RNAi screening comes of age: improved techniques and complementary approaches
Mohr, S. E., Smith, J. A., Shamu, C. E., Neumüller, R. A., & Perrimon, N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3860 · Cited by 328 · see citing works
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327 · see citing works
The Evolving Landscape of Brain Metastasis
Valiente, M., Ahluwalia, M. S., Boire, A. A., Brastianos, P. K., Goldberg, S. B., Lee, E. Q., Rhun, É. L., Preusser, M., Winkler, F., & Soffietti, R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.01.003 · Cited by 310 · see citing works
Predicting the course of Gompertzian growth
Norton, L., Simon, R. M., Brereton, H. D., & Bogdén, A. E. (1976) · Nature · doi:10.1038/264542a0 · Cited by 308 · see citing works
Toska, E., Osmanbeyoglu, H. U., Castel, P., Chan, C., Hendrickson, R. C., Elkabets, M., Dickler, M. N., Scaltriti, M., Leslie, C. S., Armstrong, S. A., et al. (2017) · Science · doi:10.1126/science.aah6893 · Cited by 262 · see citing works
Self-citationHepatic Arterial Infusion after Liver Resection
Kemeny, N. E., & Gönen, M. (2005) · New England Journal of Medicine · doi:10.1056/nejm200502173520723 · Cited by 237 · see citing works
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232 · see citing works
Wintrobe, M. M. (1949) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215 · see citing works
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.
Bosl, G. J., Gluckman, R. A., Geller, N. L., Golbey, R. B., Whitmore, W. F., Herr, H. W., Sogani, P. C., Morse, M., Martini, N., & Bains, M. S. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1493 · Cited by 198 · see citing works
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189 · see citing works
Self-citationPrinciples and Strategies for Developing Network Models in Cancer
Pe’er, D., & Hacohen, N. (2011) · Cell · doi:10.1016/j.cell.2011.03.001 · Cited by 182 · see citing works
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 169 · see citing works
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155 · see citing works
Population-based screening for cancer: hope and hype
Shieh, Y., Eklund, M., Sawaya, G. F., Black, W. C., Kramer, B. S., & Esserman, L. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.50 · Cited by 147 · see citing works
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Shaked, Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.57 · Cited by 136 · see citing works
Growth Curve of an Experimental Solid Tumor Following Radiotherapy
Norton, L., & Simon, R. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/58.6.1735 · Cited by 126 · see citing works
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0282-x · Cited by 118 · see citing works
Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · doi:10.7892/boris.110876 · Cited by 105 · see citing works
Blackburn, E. H. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0195 · Cited by 103 · see citing works
Peters, W. P., Rosner, G. L., Vredenburgh, J. J., Shpall, E. J., Crump, M., Richardson, P. G. G., Schuster, M. W., Marks, L. B., Cirrincione, C., Norton, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.202 · Cited by 100 · see citing works
Rizvi, N. A., Cho, B. C. C., Reinmuth, N., Lee, K. H., Ahn, M., Luft, A. V., van den Heuvel, M. M., Cobo, M., Smolin, A., Vicente, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy511.005 · Cited by 92 · see citing works
Chemotherapy of Pulmonary Tuberculosis
Crofton, J. (1959) · BMJ · doi:10.1136/bmj.1.5138.1610 · Cited by 88 · see citing works
Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 79 · see citing works
Exposure to anticancer drugs can result in transgenerational genomic instability in mice
Glen, C. D., & Dubrova, Y. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119396109 · Cited by 77 · see citing works
Klein, E. A., Hubbell, E. A., Maddala, T., Aravanis, A. M., Beausang, J. F., Filippova, D., Gross, S. S., Jamshidi, A., Kurtzman, K. N., Shen, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12021 · Cited by 57 · see citing works
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 55 · see citing works
Challenges in Using ctDNA to Achieve Early Detection of CancerPreprint
Haque, I. S., & Elemento, O. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/237578 · Cited by 39 · see citing works
Martin, R., Donovan, J., Turner, E., Metcalfe, C., Young, G., Walsh, E., Lane, J., Noble, S., Oliver, S., Evans, S., et al. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.24935 · Cited by 33 · see citing works
Modi, S., Tsurutani, J., Tamura, K., Park, H., Sagara, Y., Murthy, R., Iwata, H., Krop, I. E., Doi, T., Redfern, C., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-17-02 · Cited by 27 · see citing works
Wu, Y.-L. L. C., Jenkins, S. C., Ramalingam, S. S., Han, J., Delmonte, A., Hsia, T., Laskin, J. J., Kim, S., He, Y., Patel, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.436 · Cited by 24 · see citing works
Resistance through repopulation
Tannock, I. F. (2014) · Nature · doi:10.1038/nature14075 · Cited by 23 · see citing works
Elia, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197105272842119 · Cited by 22 · see citing works
Corcoran, R. B., Falchook, G. S., Infante, J. R., Hamid, O., Messersmith, W. A., DAUD, A. I., Kwak, E. L., Ryan, D. P., Kurzrock, R., Atreya, C. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3507 · Cited by 13 · see citing works
Treatment of Fractures with Hirschhorn Compression Plates
Hickcox, J. P. (1970) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.1970.156.02.187 · Cited by 8 · see citing works
Abstract 4200: Racial differences in multiple myeloma cases with anemia
Modi, R. A., Costa, L. J., & Brown, E. E. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4200 · Cited by 4 · see citing works
Versmold, H., Riegel, K. P., & Betke, K. (1975) · PubMed · Cited by 2 · see citing works
Kong, R., Bharadwaj, U., Eckols, T. K., Kasembeli, M. M., Kolosov, M. I., Tran, A., Ifelayo, O. I., Zhao, H., Wong, S. T. C., & Tweardy, D. J. (2019) · Cancer Chemistry · doi:10.1158/1538-7445.sabcs18-17 · Cited by 1 · see citing works
Flagged first, then by citations
4 of the 188 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [19]Goldie JH & Coldman AJ A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep 63, 1727– 1733 (1979). 526911
Cited by
Sorted by citations
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,267 · see citing works
Mitochondrial dynamics in health and disease: mechanisms and potential targets
Chen, W., Zhao, H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01547-9 · Cited by 1,306 · see citing works
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,175 · see citing works
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,113 · see citing works
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,070 · see citing works
Metal–Organic Frameworks for Biomedical Applications
Yang, J., & Yang, Y. (2020) · Small · doi:10.1002/smll.201906846 · Cited by 1,032 · see citing works
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., Shao, Z., & Yu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 1,098 · see citing works
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980 · see citing works
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927 · see citing works
Gerstberger, S. C., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 956 · see citing works
Zheng, S., Wang, W., Aldahdooh, J., Malyutina, A., Shadbahr, T., Tanoli, Z., Pessia, A., & Tang, J. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.004 · Cited by 733 · see citing works
Han, Y., Wang, Y., Dong, X., Sun, D., Liu, Z., Yue, J., Wang, H., Li, T., & Wang, C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac959 · Cited by 656 · see citing works
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588 · see citing works
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565 · see citing works
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454 · see citing works
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534 · see citing works
Nie, Y., Li, D., Peng, Y., Wang, S., Hu, S., Liu, M., Ding, J., & Zhou, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119513 · Cited by 536 · see citing works
Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy
Dehelean, C. A., Marcovici, I., Şoica, C., Mioc, M., Coricovac, D. E., Iurciuc, S., Cretu, O. M., & Pînzaru, I. (2021) · Molecules · doi:10.3390/molecules26041109 · Cited by 508 · see citing works
Theranostic Fluorescent Probes
Sharma, A. K., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 510 · see citing works
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 454 · see citing works
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417 · see citing works
Chalcone Derivatives: Role in Anticancer Therapy
Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021) · Biomolecules · doi:10.3390/biom11060894 · Cited by 406 · see citing works
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 394 · see citing works
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00674-x · Cited by 405 · see citing works
Metastasis-Initiating Cells and Ecosystems
Massagué, J., & Ganesh, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0010 · Cited by 372 · see citing works
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Qin, T., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 378 · see citing works
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Zhang, A., Miao, K., Sun, H., & Deng, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72534 · Cited by 368 · see citing works
Zhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 340 · see citing works
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319 · see citing works
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 322 · see citing works
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J. R., Antonia, S. J., Mok, T. S. K., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 307 · see citing works
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 315 · see citing works
Xue, C., Li, M., Zhao, Y., Zhou, J., Hu, Y., Cai, K.-Y., Zhao, Y., Yu, S., & Luo, Z. Y. (2020) · Science Advances · doi:10.1126/sciadv.aax1346 · Cited by 302 · see citing works
Lin, Z., Wu, Y., Xu, Y., Li, G., Li, Z., & Liu, T. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01650-5 · Cited by 297 · see citing works
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 298 · see citing works
Trends in the approval of cancer therapies by the FDA in the twenty-first century
Scott, E., Baines, A. C., Gong, Y. U. T., Moore, R. V., Pamuk, G. E., Saber, H., Subedee, A., Thompson, M. D., Xiao, W., Pazdur, R., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00723-4 · Cited by 291 · see citing works
Yang, J., Dai, D., Zhang, X., Teng, L., Ma, L., & Yang, Y. (2022) · Theranostics · doi:10.7150/thno.80687 · Cited by 280 · see citing works
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 274 · see citing works
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy
Fu, S., Li, G., Zang, W., Zhou, X., Shi, K., & Zhai, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.012 · Cited by 265 · see citing works
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 276 · see citing works
Rational Design in Photopharmacology with Molecular Photoswitches
Kobauri, P., Dekker, F. J., Szymański, W., & Feringa, B. L. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300681 · Cited by 265 · see citing works
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 263 · see citing works
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., Berardinis, P. D., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 256 · see citing works
Nanomaterials in tumor immunotherapy: new strategies and challenges
Zhu, X., & Li, S. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01797-9 · Cited by 257 · see citing works
Manganyi, M. C., & Ateba, C. N. (2020) · Microorganisms · doi:10.3390/microorganisms8121934 · Cited by 249 · see citing works
Longevity leap: mind the healthspan gap
Garmany, A., Yamada, S., & Terzic, A. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00169-5 · Cited by 252 · see citing works
In situ self-assembly for cancer therapy and imaging
Kim, J., Lee, S., Kim, Y., Choi, M., Lee, I., Kim, E., Yoon, C. G., Pu, K., Kang, H., & Kim, J. S. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00589-3 · Cited by 242 · see citing works
Nicolò, E., Giugliano, F., Ascione, L., Tarantino, P., Corti, C., Tolaney, S. M., Cristofanilli, M., & Curigliano, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102395 · Cited by 242 · see citing works
Bhat, A. A., Nisar, S., Singh, M. K., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12295 · Cited by 245 · see citing works
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms
Ferreira, P. M. P., de Sousa, R. W. R., Ferreira, J. R. D. O., Militão, G. C. G., & Bezerra, D. P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105582 · Cited by 236 · see citing works
Cancer drug resistance induced by EMT: novel therapeutic strategies
Rivas, J. D. L., Brozović, A., Izraely, S., Casas-Pais, A., Witz, I. P., & Figueroa, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03063-7 · Cited by 231 · see citing works
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227 · see citing works
Zhang, Y., Lou, Y., Wang, J., Yu, C., & Shen, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609705 · Cited by 232 · see citing works
Bao, W., Liu, M., Meng, J., Liu, S., Wang, S., Jia, R., Wang, Y., Ma, G., Wei, W., & Tian, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-26655-4 · Cited by 227 · see citing works
The evolutionary dynamics of extrachromosomal DNA in human cancers
Lange, J. T., Rose, J. C., Chen, C. Y., Pichugin, Y., Xie, L., Tang, J., Hung, K. L., Yost, K. E., Shi, Q., Erb, M. L., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01177-x · Cited by 221 · see citing works
The present and future of PI3K inhibitors for cancer therapy
Castel, P., Toska, E., Engelman, J. A., & Scaltriti, M. (2021) · Nature Cancer · doi:10.1038/s43018-021-00218-4 · Cited by 222 · see citing works
The mechanism of ferroptosis and its related diseases
Feng, S., Tang, D., Wang, Y., Li, X., Bao, H., Tang, C., Dong, X., Li, X., Yang, Q., Yan, Y., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00142-2 · Cited by 224 · see citing works
Cellular adaptation to cancer therapy along a resistance continuum
França, G. S., Baron, M., King, B. R., Bossowski, J. P., Bjornberg, A., Pour, M., Rao, A. N., Patel, A. S., Misirlioğlu, S., Barkley, D., et al. (2024) · Nature · doi:10.1038/s41586-024-07690-9 · Cited by 227 · see citing works
Wu, W., Yu, L., Pu, Y., Yao, H., Chen, Y., & Shi, J. (2020) · Advanced Materials · doi:10.1002/adma.202000542 · Cited by 216 · see citing works
El‐Saadony, M. T., Saad, A. M., Mohammed, D. M., Korma, S. A., Alshahrani, M. Y., Ahmed, A. E., Ibrahim, E. H., Salem, H. M., Alkafaas, S. S., Saif, A. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1491777 · Cited by 269 · see citing works
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 202 · see citing works
Liu, J., Yuan, Y., Cheng, Y., Fu, D., Chen, Z., Wang, Y., Zhang, L., Yao, C., Shi, L., Li, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11856 · Cited by 205 · see citing works
Exosomes and breast cancer drug resistance
Dong, X., Bai, X., Ni, J., Zhang, H., Duan, W., Graham, P., & Li, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03189-z · Cited by 202 · see citing works
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · see citing works
Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system
Hari, S. K., Gauba, A., Shrivastava, N., Tripathi, R. M., Jain, S. K., & Pandey, A. K. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01197-4 · Cited by 197 · see citing works
The two sides of chromosomal instability: drivers and brakes in cancer
Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01767-7 · Cited by 205 · see citing works
Yang, Y., Li, S., To, K. K. W., Zhu, S., Wang, F., & Fu, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03377-9 · Cited by 195 · see citing works
Zhao, Q., Huang, L., Qin, G., Qiao, Y., Ren, F., Shen, C., Wang, S., Liu, S., Lian, J., Wang, D., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.009 · Cited by 190 · see citing works
Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4140 · Cited by 194 · see citing works
Anticancer Activity of Natural and Synthetic Chalcones
Constantinescu, T., & Lungu, C. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111306 · Cited by 192 · see citing works
Xiao, Q., Zhao, W., Wu, C., Wang, X., Chen, J., Shi, X., Sha, S., Li, J., Liang, X., Yang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105274 · Cited by 193 · see citing works
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 201 · see citing works
Aneuploidy-Driven Genome Instability Triggers Resistance to Chemotherapy
Ippolito, M. R., Martis, V., Martin, S., Tijhuis, A. E., Hong, C., Wardenaar, R., Dumont, M., Zerbib, J., Spierings, D. C. J., Fachinetti, D., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2021.07.006 · Cited by 191 · see citing works
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Hazaveh, M. N., Khosravi, S., Andani, M. K., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 193 · see citing works
Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Castro, M. D. C. C., Deese, A. R., & Li, Z. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 193 · see citing works
Saponins in Cancer Treatment: Current Progress and Future Prospects
Elekofehinti, O. O., Iwaloye, O., Olawale, F., & Ariyo, E. O. (2021) · Pathophysiology · doi:10.3390/pathophysiology28020017 · Cited by 184 · see citing works
Novel nanomedicines to overcome cancer multidrug resistance
Su, Z., Dong, S., Zhao, S., Liu, K., Tan, Y., Jiang, X., Assaraf, Y. G., Qin, B., Chen, Z., & Zou, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100777 · Cited by 184 · see citing works
Jung, K., Corrigan, N. A., Wong, E. H. H., & Boyer, C. A. (2021) · Advanced Materials · doi:10.1002/adma.202105063 · Cited by 189 · see citing works
Noncoding RNAs regulate alternative splicing in Cancer
Liu, Y., Liu, X., Lin, C., Jia, X., Zhu, H., Song, J. H., & Zhang, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01798-2 · Cited by 183 · see citing works
Li, Z., Xu, W., Yang, J.-Z., Wang, J., Wang, J., Zhu, G., Li, D., Ding, J., & Sun, T. (2022) · Advanced Materials · doi:10.1002/adma.202200449 · Cited by 181 · see citing works
In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts
Huang, C., Liang, C., Sadhukhan, T., Banerjee, S., Fan, Z., Li, T., Zhu, Z., Zhang, P., Raghavachari, K., & Huang, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202015671 · Cited by 174 · see citing works
Activatable fluorescent probes for real-time imaging-guided tumor therapy
Duan, Q.-J., Zhao, Z., Zhang, Y., Fu, L., Yuan, Y., Du, J., & Wang, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114793 · Cited by 167 · see citing works
Impact of cancer metabolism on therapy resistance – Clinical implications
Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B. R. G., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento‐Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 169 · see citing works
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Cerezo‐Wallis, D., Contreras-Alcalde, M., Troulé, K., Catena, X., Mucientes, C., Calvo, T. G., Cañón, E., Tejedo, C., Pennacchi, P. C., Hogan, S. A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1073-3 · Cited by 161 · see citing works
Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163 · see citing works
Shi, T., Hou, X., Guo, S., Zhang, L., Wei, C., Peng, T., & Hu, X. (2021) · Nature Communications · doi:10.1038/s41467-020-20547-9 · Cited by 161 · see citing works
Chronic Inflammation and Blood CancerPreprint
Tzenios, N., Tazanios, M., & Chahine, M. A. (2022) · Preprints.org · doi:10.20944/preprints202211.0365.v2 · Cited by 161 · see citing works
Perplexing Role of P-Glycoprotein in Tumor Microenvironment
Robinson, K., & Tiriveedhi, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00265 · Cited by 159 · see citing works
Clonal fitness inferred from time-series modelling of single-cell cancer genomes
Salehi, S., Kabeer, F., Ceglia, N., Andronescu, M., Williams, M. J., Campbell, K. R., Masud, T., Wang, B., Biele, J., Brimhall, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03648-3 · Cited by 144 · see citing works
Guan, Q., Wang, G.-B., Zhou, L., Li, W., & Dong, Y. (2020) · Nanoscale Advances · doi:10.1039/d0na00537a · Cited by 148 · see citing works
Manley, P. W., Barys, L., & Cowan‐Jacob, S. W. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106458 · Cited by 147 · see citing works
Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Gilad, Y., Gellerman, G., Lonard, D. M., & O’Malley, B. W. (2021) · Cancers · doi:10.3390/cancers13040669 · Cited by 146 · see citing works
Zhang, J., Simpson, C. M., Berner, J., Chong, H. B., Fang, J., Ordulu, Z., Weiss‐Sadan, T., Possemato, A. P., Harry, S. A., Takahashi, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.026 · Cited by 146 · see citing works
Lin, Z., Li, J., Zhang, J., Feng, W., Lu, J., Ma, X., Ding, W., Ouyang, S., Lu, J., Yue, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3059 · Cited by 145 · see citing works
Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
Liang, P., Ballou, B. T., Lv, X., Si, W., Bruchez, M. P., Huang, W., & Dong, X. (2021) · Advanced Materials · doi:10.1002/adma.202005155 · Cited by 144 · see citing works
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 152 · see citing works
Zhang, K.-R., Zhang, Y.-F., Lei, H.-M., Tang, Y., Ma, C., Lv, Q.-M., Wang, S.-Y., Lu, L., Shen, Y. H., Chen, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg6428 · Cited by 142 · see citing works
Lin, H., Wang, D., Wang, P., Long, F., & Wang, T. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01620-x · Cited by 141 · see citing works
P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer
Yao, D., Li, C., Rajoka, M. S. R., He, Z., Huang, J., Wang, J., & Zhang, J. C. (2020) · Theranostics · doi:10.7150/thno.46913 · Cited by 138 · see citing works
- Authors
- Vasan, N., Baselga, J., & Hyman, D. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Hyman, David M.
- Venue
- Nature
- Published
- 2019-11-13
- Volume
- 575
- Issue
- 7782
- Pages
- 299-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8008476
- OpenAlex
- W2988773550
- Cited by
- 2,770
- References
- 188
- Citations by year
- 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Eli Lilly and Company
- National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
- MeSH terms
- Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
